Milestone Pharmaceuticals Inc.
Every calculator, already run for MIST
Open the full toolkit →You have the numbers on MIST. Get the argument.
A written report on which of these readings actually decide the outcome for Milestone Pharmaceuticals Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering MISTAnalyst Price Target Disagreement for Milestone Pharmaceuticals Inc.
Wall Street's bull case implies +1031% from the current price; the bear case implies +183%. A 848% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MIST
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
MIST — frequently asked
Is MIST a buy right now?
Wall Street's consensus rating on Milestone Pharmaceuticals Inc. is Strong Buy across 7 analysts, with a mean price target of $5.86 (+728% vs. the current $0.71). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is MIST's next earnings date?
Milestone Pharmaceuticals Inc. is next scheduled to report earnings around Nov 12, 2026. A full MIST research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Milestone Pharmaceuticals Inc.?
Analysts covering Milestone Pharmaceuticals Inc. (MIST) range from a bear-case target of $2.00 to a bull-case high of $8.00, with a mean consensus target of $5.86 across 7 analysts. The spread of $6.00 (848% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Milestone Pharmaceuticals Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Milestone Pharmaceuticals Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MIST research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Milestone Pharmaceuticals Inc., in minutes. 3 free reports included with every account — no credit card required.